Loss of human leucocyte antigen class I and gain of class II expression are early events in carcinogenesis: Clues from a study of Barrett's oesophagus

Journal of Clinical Pathology

Volumn 59, Issue 9, 2006, Pages 952-957

  Rajendra, S ^a,b   Ackroyd, R ^c   Karim, N ^d   Mohan, C ^e   Ho, J J ^b   Kutty, M K ^f  

^a LAUNCESTON GENERAL HOSPITAL   (Australia)

^b UNIVERSITI KUALA LUMPUR   (Malaysia)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^d HOSPITAL RAJA PERMAISURI BAINUN   (Malaysia)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITI TEKNOLOGI MARA   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BARRETT ESOPHAGUS; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; DYSPLASIA; ENDOSCOPY; FEMALE; HISTOPATHOLOGY; HLA SYSTEM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MALIGNANT TRANSFORMATION; PHENOTYPE; PRIORITY JOURNAL; SQUAMOUS CELL; UPREGULATION;

ADULT; AGED; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS;

EID: 33748869157     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.031575     Document Type: Article

References (33)

1. Hameeteman W, Tytgat GNJ, Houthoff HJ, et al. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989;96:1249-56.
2. Jankowski J. Gene expression in Barrett's s mucosa: acute and chronic adaptive responses in the oesophagus. Gut 1993;34:1649-50.
3. Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M, et al. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut 2002;50:451-59.
4. Little AM, Stern PL. Does HLA type predispose some individuals to cancer? MolMed Today, 1999;5:337-42.
5. Scanlan AAJ, Chen YT, Williamson B, et al. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 1998;76:652-58.
6. Townsend A, Ohlen C, Bastin J, et al. Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature 1989;340:443-48.
7. Rajendra S, Ackroyd R, Murad S, et al. HLA determinants of susceptibility to Barrett's oesophagus in Asians: a preliminary report. Aliment Pharmacol Ther 2005;21:1377-83.
8. Garrido F, Ruiz-Cabello F. MHC expression on human tumors-its relevance for local tumor growth and metastasis. Semin Cancer Biol 1991;2:3-10.
9. Lopez Nevot MA, Esteban F, Ferron A, et al. HLA class I gene expression on human primary tumours and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br J Cancer 1989;59:221-26.
10. Esteban F, Ruiz-Cabello F, Concha A, et al. HLA-DR expression is associated with excellent prognosis in squamous cell carcinoma of the larynx. Clin Exp Metast 1990;8:319-28.
11. Garrido F, Ruiz-Cabello F, Cabrera T, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol Today 1997;18:89-95.
12. Pujol-Borrell R, Todd I, Londei M, et al. Inappropriate major histocompatibility complex class II expression by thyroid follicular cells in thyroid autoimmune disease and by pancreatic beta cells in type I diabetes. J Mol Biol Med 1986;3:159-65.
13. Rockett JC, Darnton SJ, Cracker J, et al. Expression of HLA-ABC, HLA-DR and intercellular adhesion molecule-1 in oesophageal carcinoma. J Clin Pathol 1995;48:539-44.
14. Rajnakovo A, Goh PMY, Chan STF, et al. Expression of differential nitric oxide synthase isoforms in human normal gastric mucosa and gastric cancer tissue. Carcinogenesis 1997;18:1841-45.
15. Cameron AJ, Lomboy CT. Barrett's oesophagus: age, prevalence and extent of columnar epithelium. Gastroenterology 1992;103:1241-5.
16. Cromme FV, Meijer CJ, Snijders PJ, et al. Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions. Br J Cancer 1993;67:1372-80.
17. Bontkes HJ, Walboomers JM, Meijer CJ, et al. Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression. Lancet 1998;351:187-8.
18. Garrido F, Cabrera T, Lopez-Nevot MA, et al. HLA class I antigens in human tumours. Adv Cancer Res 1995;67:155-95.
19. Nie Y, Yang GU, Song Y, et al. DNA hypermethylation is a mechanism for loss of expression of HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis 2001;22:1615-23.
20. Algarra I, Cabrera T, Garrido F. The HLA crossroad in tumor immunology. Hum Immunol 2000;61:65-73.
21. Hilders CG, Munoz IM, Nooyen Y, et al. Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance. Gynecol Oncol 1995;57:366-75.
22. 2 microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 1998;52:520-9.
23. 2 m gene expression. J Clin Invest 1991;87:284-92.
24. Blanchet O, Bourge JF, Zinszer H, et al. DNA binding of regulatory factor interacting with MHC-class I gene enhancer correlates with MHC class transcriptional level in class I defective cell lines. Int J Cancer 1991;6:138-45.
25. Cromme FV, Airey J, Heemels MT, et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994;179:335-40.
26. Torres MJ, Ruiz-Cabello F, Skoudy A, et al. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tissue Antigens 1996;47:372-81.
27. Garrido F, Cabrera T, Concha A, et al. Natural history of HLA expression during tumour development. Immunol Today 1993;14:491-9.
28. Lazaris AC, Theodoropoulos GE, Davaris PS, et al. Heat shock protein 70 and HLA-DR molecules tissue expression. Prognostic implications in colorectal cancer. Dis Colon Rectum 1995;38:739-45.
29. Oberrhuber G, Puspok A, Peck-Radosavlevic M, et al. Aberrant esophageal HLA-DR expression in a high percentage of patients with Crohn's disease. Am J Surg Pathol, 1998;22:383-90.
30. Lampert IA, Janosssy G, Suitters AJ, et al. Immunological analysis of the skin on graft verus host disease. Clin Exp Immunol 1982;50:123-31.
31. Selby WS, Janossy G Mason DY, et al. Expression of HLA-DR antigens by colonic epithelium in inflammatory bowel disease. Clin Exp Immunol 1983;53:014-18.
32. Scott H, Brandtzaeg P, Solheim BG, et al. Relationship beweert HLA-DR-like antigens and secretory component (SC) in jejunal epithelium of patients with celiac disease or dermatitis herpetiformis. Clin Exp Immunol 1981;44:233-8.
33. Corley DA, Kerlikowske K, Verma R, et al. Protective association of aspirin/NSAID's and oesophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003;124:47-56.